This Big Pharma stock is one of the safest bets, according to the Mad Money host, and it plays an attractive dividend to ...

Indeed, a recent study in JAMA Network Open is the first to suggest that even protection from certain cancers could be among the ways these drugs can help improve health. People with obesity have ...

The FDA determined in December and February, respectively, that the companies could meet demand. Grace periods for the compounding pharmacies expired this spring. Some have already stopped compounding ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Despite an increase in the prevalence of prescribing, only 0.5% of U.S. adolescents with obesity were prescribed an obesity medication in 2023, according to research published in the June 5 issue ...

Just 0.5% with obesity were prescribed an obesity medication in 2023; 83% of prescriptions received by teens with severe obesity. HealthDay News — Despite an increase in the prevalence of ...

Obesity, diabetes and cardiovascular diseases are increasingly present in the population. Brown adipose tissue has a protective function against these prevalent diseases, as it burns calories and ...

AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market.

Objective The gut microbiota has been implicated as an environmental factor that modulates obesity, and recent evidence suggests that microbiota-mediated changes in bile acid profiles and signalling ...

HØRSHOLM, DK / ACCESS Newswire / June 3, 2025 / Gubra (CPH:GUBRA) Notice to convene extraordinary GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND GUBRA A/SCVR NO. 30 51 40 41 To the shareholders ...

AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market.